Diagnóstico e Seguimento Laboratorial de Doentes com Mieloma Múltiplo: Recomendações do Grupo Português do Mieloma Múltiplo
DOI:
https://doi.org/10.20344/amp.22909Palavras-chave:
Guias de Prática Clínica, Mieloma Múltiplo/diagnóstico, Mieloma Múltiplo/sangue, Portugal, Técnicas de Laboratório ClínicoResumo
O mieloma múltiplo é uma neoplasia de plasmócitos que, na maioria dos casos, se associa à secreção de imunoglobulinas monoclonais e que pode cursar com um atingimento multiorgânico. O diagnóstico atempado do mieloma múltiplo é essencial para evitar ou limitar danos irreversíveis e disfunção dos órgãos-alvo. A apropriada estratificação inicial dos doentes permite otimizar a seleção e a sequência da terapêutica, assim como o correto seguimento durante o tratamento, com impacto na sobrevivência. As presentes recomendações laboratoriais do Grupo Português do Mieloma Múltiplo oferecem orientações para o diagnóstico e seguimento laboratorial dos doentes com mieloma múltiplo. O seguimento e diagnóstico de doentes com outras gamapatias monoclonais de significado clínico não foram incluídos neste texto. A sua elaboração tem por base orientações internacionais, publicações científicas e experiência de um painel de especialistas nacionais das áreas clínicas e laboratoriais dedicados ao estudo e tratamento do mieloma múltiplo.
Downloads
Referências
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48. DOI: https://doi.org/10.1016/S1470-2045(14)70442-5
Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069-75. DOI: https://doi.org/10.1182/blood-2014-09-568899
Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-9. DOI: https://doi.org/10.1056/NEJMoa01133202
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-90. DOI: https://doi.org/10.1056/NEJMoa070389
Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478-85. DOI: https://doi.org/10.1182/blood-2018-04-839480
Thoren KL, McCash SI, Murata K. Immunotyping provides equivalent results to immunofixation in a population with a high prevalence of monoclonal gammopathies. J Appl Lab Med. 2021;6:1551-60. DOI: https://doi.org/10.1093/jalm/jfab067
Yang Z, Harrison K, Park YA, Chaffin CH, Thigpen B, Easley PL, et al. Performance of the sebia CAPILLARYS 2 for detection and immunotyping of serum monoclonal paraproteins. Am J Clin Pathol. 2007;128:293-9. DOI: https://doi.org/10.1309/1L3CG8GK6F8VYNYH
McCudden CR, Mathews SP, Hainsworth SA, Chapman JF, Hammett-Stabler CA, Willis MS, et al. Performance comparison of capillary and agarose gel electrophoresis for the identification and characterization of monoclonal immunoglobulins. Am J Clin Pathol. 2008;129:451-8. DOI: https://doi.org/10.1309/6KT8N49BRNVVVBT1
Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54:907-19. DOI: https://doi.org/10.1515/cclm-2015-0580
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-46. DOI: https://doi.org/10.1016/S1470-2045(16)30206-6
Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517-22. DOI: https://doi.org/10.1373/clinchem.2009.126664
Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia. 2019;33:313-8. DOI: https://doi.org/10.1038/s41375-018-0339-y
Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res. 2005;11:8706-14. DOI: https://doi.org/10.1158/1078-0432.CCR-05-0486
Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, et al. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Am J Hematol. 2018;93:1207-10. DOI: https://doi.org/10.1002/ajh.25215
Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11. DOI: https://doi.org/10.1186/1471-2369-9-11
Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:133. DOI: https://doi.org/10.1038/s41408-022-00732-3
Ríos-Tamayo R, Puig N, Algarín M, García de Veas Silva JL, Barbosa N, Encinas C, et al. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: an evidence-based approach. Diagnostics. 2021;11:2020. DOI: https://doi.org/10.3390/diagnostics11112020
Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, et al. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol. 2016;174:81-7. DOI: https://doi.org/10.1111/bjh.14026
Ludwig H, Milosavljevic D, Berlanga O, Zojer N, Hübl W, Fritz V, et al. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. Am J Hematol. 2016;91:295-301. DOI: https://doi.org/10.1002/ajh.24268
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, et al. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2024;109:1909-17. DOI: https://doi.org/10.3324/haematol.2023.284154
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25:e374-87. DOI: https://doi.org/10.1016/S1470-2045(24)00094-9
Bain BJ, Clark DM, Wilkins BS. Bone marrow pathology. New Jersey: Wiley-Blackwell; 2019. DOI: https://doi.org/10.1002/9781119398929
Caers J, Garderet L, Kortüm KM, O’dwyer ME, van de Donk NW, Binder M, et al. European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018;103:1772-84. DOI: https://doi.org/10.3324/haematol.2018.189159
Ribourtout B, Zandecki M. Plasma cell morphology in multiple myeloma and related disorders. Morphologie. 2015;99:38-62. DOI: https://doi.org/10.1016/j.morpho.2015.02.001
Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22:5428-33. DOI: https://doi.org/10.1158/1078-0432.CCR-16-0866
Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30:349-64. DOI: https://doi.org/10.1111/j.1751-553X.2008.01100.x
Takakuwa T, Araki T, Nakamura K, Fukuyama T, Miura A, Fujitani Y, et al. Morphologic classification is an important prognostic factor in patients with newly diagnosed multiple myeloma treated with bortezomib or lenalidomide. Ann Clin Lab Sci. 2020;50:333-41.
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60. DOI: https://doi.org/10.1056/NEJMra1011442
Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780-91. DOI: https://doi.org/10.1038/leu.2012.336
Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11:192. DOI: https://doi.org/10.1038/s41408-021-00587-0
van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908-75. DOI: https://doi.org/10.1038/leu.2012.120
Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-8. DOI: https://doi.org/10.3324/haematol.11080
Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O’Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272-7. DOI: https://doi.org/10.3324/haematol.2011.056176
Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32:102-10. DOI: https://doi.org/10.1038/leu.2017.179
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911-20. DOI: https://doi.org/10.1200/JCO.2014.59.1503
Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020;95:310-5. DOI: https://doi.org/10.1002/ajh.25709
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-8. DOI: https://doi.org/10.1038/leu.2013.313
Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801-8. DOI: https://doi.org/10.1038/s41375-021-01453-5
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-21. DOI: https://doi.org/10.1038/leu.2009.174
Caetano J, Barahona F, Lúcio P, João C. Measurable residual disease assessment in multiple myeloma: how deep is enough? Hemato. 2022;3:385-413. DOI: https://doi.org/10.3390/hemato3030027
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988-99. DOI: https://doi.org/10.1182/bloodadvances.2020002827
Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35:2900-10. DOI: https://doi.org/10.1200/JCO.2016.69.2517
Food and Drug Administration. April 12, 2024 meeting of the oncologic drugs advisory committee meeting announcement. [cited 2024 Jun 23]. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024.
Zaninotto M, Graziani MS, Plebani M. The harmonization issue in laboratory medicine: the commitment of CCLM. Clin Chem Lab Med. 2023;61:721-31. DOI: https://doi.org/10.1515/cclm-2022-1111
Singh G. Serum and urine protein electrophoresis and serum-free light chain assays in the diagnosis and monitoring of monoclonal gammopathies. J Appl Lab Med. 2020;5:1358-71. DOI: https://doi.org/10.1093/jalm/jfaa153
Booth RA, McCudden CR, Balion CM, Blasutig IM, Bouhtiauy I, Rodriguez-Capote K, et al. Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group. Clin Biochem. 2018;51:10-20. DOI: https://doi.org/10.1016/j.clinbiochem.2017.10.013
Tate JR, Keren DF, Mollee P. A global call to arms for clinical laboratories – harmonised quantification and reporting of monoclonal proteins. Clin Biochem. 2018;51:4-9. DOI: https://doi.org/10.1016/j.clinbiochem.2017.11.009
Moss MA. Moving towards harmonized reporting of serum and urine protein electrophoresis. Clin Chem Lab Med. 2016;54:973-9. DOI: https://doi.org/10.1515/cclm-2015-0937
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955-62. DOI: https://doi.org/10.1182/blood-2016-01-631200
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159-70. DOI: https://doi.org/10.1038/s41375-018-0196-8
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094-103. DOI: https://doi.org/10.1038/leu.2017.29
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31-9. DOI: https://doi.org/10.1002/cyto.b.21228
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2025 Acta Médica Portuguesa
Este trabalho encontra-se publicado com a Creative Commons Atribuição-NãoComercial 4.0.
Todos os artigos publicados na AMP são de acesso aberto e cumprem os requisitos das agências de financiamento ou instituições académicas. Relativamente à utilização por terceiros a AMP rege-se pelos termos da licença Creative Commons ‘Atribuição – Uso Não-Comercial – (CC-BY-NC)’.
É da responsabilidade do autor obter permissão para reproduzir figuras, tabelas, etc., de outras publicações. Após a aceitação de um artigo, os autores serão convidados a preencher uma “Declaração de Responsabilidade Autoral e Partilha de Direitos de Autor “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) e a “Declaração de Potenciais Conflitos de Interesse” (http://www.icmje.org/conflicts-of-interest) do ICMJE. Será enviado um e-mail ao autor correspondente, confirmando a receção do manuscrito.
Após a publicação, os autores ficam autorizados a disponibilizar os seus artigos em repositórios das suas instituições de origem, desde que mencionem sempre onde foram publicados e de acordo com a licença Creative Commons
